Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Patients diagnosed with Multifocal Motor Neuropathy were confirmed based on the European
Federation of Neurological Societies/ Peripheral. Nerve Society Guideline. Patients who meet
all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01
(intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, patients
receive NPB-01 1g/kg every 3weeks and evaluate the Medical Research Council（MRC） score and
the Guy's Neurological Disability Scale（GNDS） et al.
As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse
events by one year after the start of the study treatment.